Unusual Clinical Presentations of Cortical-Basal Ganglionic Degeneration
Ann Neurol 40:893-900, Bergeron,C.,et al, 1996
Progressive Supranuclear Palsy:Neuropathologic and Clinical Heterogeneity
Neurol 44:1015-1024, Gearing,M.,et al, 1994
Delayed Encephalopathy after Acute Carbon Monoxide Intoxication:MR Imaging Features & Cerebral White Matter Lesions
Radiology 184:117-122, Chang,K.H.,et al, 1992
Cortical Lewy Body Dementia:Clinical Features and Classification
JNNP 52:185-192, Gibb,W.R.G.,et al, 1989
Dose-Dependent Memory Impairment in Parkinson's Disease
Neurol 39:438-440, Huber,S.J.,et al, 1989
Drug-Induced Alzheimerism
Arch Neurol 45:356-357, Kurlan,R.&Como,P., 1988
Diffuse Lewy Body Disease and Progressive Dementia
Neurol 38:1520-1528, Burkhardt,C.R.,et al, 1988
Clinical & Biochemical Correlates of Bradyphrenia in Parkinson's Disease
Neurol 37:1130-1134, Mayeux,R.,et al, 1987
Nervous System Toxicity of Chemo Agents
Young, DF, in Vinken PJ, Bruyn GW, Handbook of Clin Neurol, North-Holland Publ Co, Amster, Vol 39, 1, 80, p 104, 1980
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Neurologic Manifestations in Welders with Pallidal MRI T1 Hyperintensity
Neurol 64:2033-2039,2001, Josephs,K.A.,et al, 2005
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Treatment of Advanced Parkinson's Disease by Posterior GPi Pallidotomy:1-Year Results of a Pilot Study
Ann Neurol 40:355-366, 3411996., Baron,M.S.,et al, 1996
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field
Ann Neurol 90:711-719, Verger, A.,et al, 2021
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020
A 58-year-old Man with Hand Tremor and Episodes of Neck Pain
Neurol 93:557-561, Urso, D.,et al, 2019
The Parkinson Pandemic - A Call to Action
JAMA Neurol 75:9-10, Dorsey, E.R. & Bloem, B.R., 2018
MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?
AJNR 38:1737-1741, Shams, S.,et al, 2017
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Gait Freezing and Speech Disturbance in Parkinsons Disease
Neurol Sci 35:357-363, Park,H.K.,et al, 2014
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Arch Neurol 68:899-904, Weintraub, D.,et al, 2011
What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Road Safety in Drivers With Parkinson Disease
Neurol 73:2112-2119, Uc,E.,et al, 2009
Dementia and Survival in Parkinson Disease: A 12-Year Population Study
Neurol 70:1017-1022, Buter,T.C.,et al, 2008
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD gene for Parkinsons Disease: An Open Label, Phase I Trial
Lancet 369:2097-2105,2056, Kaplitt,M.G.,et al, 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Predictors of Fitness to Drive in People With Parkinson Disease
Neurol 69:1434-1441, Devos,H.,et al, 2007
Parkinson Disease, 10 Years After Its Genetic Revolution: Multiple Clues to a Complex Disorder
Neurol 69:2093-2104, Klein,C. &Schlossmacher,M.G., 2007
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006
Atypical Antipsychotics in the Elderly with Parkinson Disease and the "Black Box" Warning
Neurol 67:564-566, Friedman,J.H., 2006
Impaired Visual Search in Drivers with Parkinsons Disease
Ann Neurol 60:407-413,387, Uc,E.Y.,et al, 2006
Donepezil for Dementia in Parkinsons Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study
JNNP 76:934-939,903, Ravina,B.,et al, 2005
Neuropathology of Dementia in Parkinsons Disease: A Prospective, Community-Based Study
Ann Neurol 58:773-776,663, Aarsland,D.,et al, 2005
Autonomic Failure as the Initial Presentation of Parkinson Disease and Dementia with Lewy Bodies
Neurol 63:1093-1095, Kaufmann,H.,et al, 2004
Rivastigmine for Dementia Associated with Parkinson's Disease
NEJM 351:2509-2518,2547, Emre,M.,et al, 2004
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Pract Neurology 4:50-55, Razvi,S.S.M. &Muir,K.W., 2004